The Access to COVID-19 Tools (ACT-) Accelerator published its consolidated investment case on Friday, calling for US$31.3 billion over the next 12 months to accelerate tests, treatments and vaccines for the whole world.
Only US$3.4 billion has been pledged so far, leaving a gap of US$27.9 billion — of which US$13.7 billion is urgently needed.
The investment case and the costed plans of each partner organization were published by the WHO, which launched the Accelerator at the end of April with the President of France, the President of the European Commission and The Bill & Melinda Gates Foundation, in response to a call from G20 leaders in March, WHO reported.
Plan sets 500 million tests and 2 billion vaccine doses
- The plan sets concrete delivery targets: 500 million diagnostic tests and 245 million courses of treatment for low- and middle-income countries by mid-2021, and 2 billion vaccine doses by the end of 2021 — half of them for those same countries.
- The full ask, US$31.3 billion, is less than a tenth of what the IMF estimates the global economy is losing every month because of the pandemic.
- 468,000 people have already lost their lives to COVID-19, and the tools funded here are aimed at cutting deaths and severe disease rather than replacing public health measures.
What the $31.3 billion actually buys
The Accelerator is not a new organization or a decision-making body. It is a framework that pulls existing organizations together across four pillars — diagnostics, therapeutics, vaccines and a health systems connector — each with its own costed plan published on Friday.
The investment case frames the goal in clinical terms: saving lives and reducing severe COVID-19 disease, protecting health systems, and restoring full societal and economic activity globally in the near term, with high-level control of the disease in the medium term.
Diagnostics: the pillar that gates the others
Two organizations share leadership of the diagnostics pillar: FIND and the Global Fund to Fight AIDS, Tuberculosis and Malaria. If it receives adequate financing, the pillar’s goals are to get 2–3 high-quality rapid tests onto the market, provide training to 10,000 healthcare professionals spanning 50 countries, and put testing capacity in place for 500 million people in low- and middle-income countries by mid-2021.
WHO frames this pillar as the hinge for everything else: test, trace and isolate strategies determine how quickly health services avoid disruption, and how ready countries are to roll out treatments and vaccines once they exist. The pillar’s own estimate is that equitable access to simple, accurate and affordable tests can save 9 million lives and avoid 1.6 billion further infections.
Therapeutics pillar targets 245 million treatment courses
The therapeutics pillar, led by Unitaid and the Wellcome Trust on behalf of the COVID-19 Therapeutics Accelerator, targets development, manufacture, procurement and equitable distribution of 245 million courses of treatment for low- and middle-income countries within 12 months, at all stages of disease.
The vaccine pillar combines CEPI’s development and manufacturing investment, GAVI’s delivery track record and WHO’s oversight of regulation, policy and allocation. Delivering 2 billion doses by the end of 2021 — assuming a safe and effective vaccine is developed — is estimated at up to US$18.1 billion.
On top of that, 950 million doses are to be procured by self-financing high-income and upper middle-income countries through the COVAX Facility. WHO notes these numbers will firm up once the technology behind successful candidates and the number of doses needed per person are clearer.
The funding gap, in numbers
| Pillar / need | Target | Cost or funding |
|---|---|---|
| Total investment case (12 months) | Tests, treatments, vaccines | US$31.3 billion |
| Pledged to date | — | US$3.4 billion |
| Remaining gap | — | US$27.9 billion (US$13.7 billion urgent) |
| Diagnostics | 500 million tests, LMICs, mid-2021 | 9 million lives saved (est.) |
| Therapeutics | 245 million courses, LMICs, mid-2021 | — |
| Vaccines | 2 billion doses, end-2021 (1 billion LMICs) | Up to US$18.1 billion |
An additional US$1.7 billion has been pledged for health systems, outside the US$3.4 billion counted above. The health systems connector — led by the World Bank and the Global Fund, supported by the WHO — builds the laboratory capacity, staff training and protective equipment management needed to deploy new tools, alongside contact tracing, distancing and isolation approaches.
Why the gap matters for low- and middle-income countries
The central design principle is equitable allocation: the pillars will both develop tools and buy and deliver them so that low- and middle-income countries have access, not just wealthy markets. Half of the 2 billion vaccine doses are earmarked for those countries. Without funded procurement, access would depend on national purchasing power — the mechanism the COVAX Facility is designed to offset for the 950 million self-financed doses.
The next dated step is on Saturday, June 27: the Global Goal: Unite for Our Future campaign, concert and summit, where world leaders, corporations and philanthropists are to announce new commitments to equitable distribution of tests, treatments and vaccines and to rebuilding communities hit by the pandemic.
No vaccine or therapy has completed regulatory review
No vaccine or COVID-19 therapy has yet completed the regulatory review described here; the vaccine targets are explicitly conditional on a safe and effective candidate being developed. The ACT-Accelerator also highlights isolation approaches, alongside contact tracing and social distancing, as measures needed to help combat COVID-19.
The ACT-Accelerator has already moved beyond planning in some areas. Its diagnostics partners have evaluated more than 50 diagnostic tests, and on 28 September 2020 they announced they would make 120 million affordable, quality COVID-19 rapid tests available for low- and middle-income countries. The therapeutics pillar is analysing over 1,700 clinical trials and has secured dexamethasone for up to 2.9 million patients in low-income countries.
The vaccine pillar, also known as COVAX, represents the largest and most varied portfolio of COVID-19 vaccines globally, containing over 10 vaccine candidates, and its COVAX Facility for global procurement has engaged more than 180 countries. The Health Systems connector has surveyed over 100 countries to identify health system bottlenecks and capacity gaps.
The open question
The plans published Friday lay out a delivery path through mid-2021, but the money is not yet in place: US$27.9 billion of the US$31.3 billion remains unpledged, and WHO has flagged that vaccine cost estimates could shift with the underlying technology and dose requirements. Whether the summit commitments close the urgent US$13.7 billion shortfall is not yet known.
References
- World Health Organization — ACT-Accelerator update: investment case and costed plans, June 26, 2020.
- ACT-Accelerator consolidated economic investment case (PDF), WHO.
- ACT-Accelerator pillar investment cases (diagnostics, therapeutics, vaccines), WHO, June 26, 2020.
Worth a look
- Public Health Guidance Urges Higher Fiber Intake; Experts Warn on Labels
- Registered Sex Offender Sentenced to 25 Years for Aggravated Child Abuse of 3-Year-Old
- Metronet Hiring Remote Commercial Property Access Specialist for Des Moines Territory (news-usa.today)
- GTA 6: Satire, Missing Darts, Dropped Park & 1.5M US Xbox Users Switch Region for Early Access (world-today-journal.com)